Pharmacological studies are still in a very early stage; however, the first results indeed show an in vitro efficacy of G12V-reactive CD4+ T cells against KRAS G12V-mutant NSCLC cells [66, 120]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.